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neuropathogen. We engineered intertypic gD-exchange mutants with 27 
BoHV-1- and BoHV-5-backbones in order to address their in vitro and 28 
in vivo host range, with particular interest on invasion of the brain. 29 
The new viruses replicated in cell culture with similar dynamics and to 30 
comparable titers as their wild type parents. However, gD of BoHV-5 31 
(gD5) was able to interact with a surprisingly broad range of nectins.  32 
In vivo, gD5 provided a virulent phenotype to BoHV-1 in AR129 mice, 33 
featuring high incidence of neurological symptoms and early onset of 34 
disease. However, only virus with BoHV-5-backbone, independent of 35 
the gD-type, was detected in the brain by immunohistology. Thus, gD 36 
of BoHV-5 confers an extended cellular host range to BoHV-1 and 37 
may be considered as a virulence factor but does not contribute to 38 
the invasion of the brain.  39 
Keywords 40 
Bovine herpesviruses; host-range; virulence 41 
Introduction 42 
Bovine herpesviruses 1 and 5 (BoHV-1 and BoHV-5) belong to the 43 
subfamily Alphaherpesvirinae and are closely related pathogens of 44 
cattle (22). The protein repertoire of the two viruses averages 82% 45 
amino acid identity (21). Both viruses are neurotropic but only BoHV-46 
5 can significantly replicate in the central nervous system (CNS) to 47 
cause encephalitis of either naturally infected cattle or experimentally 48 
inoculated laboratory animals (2, 5, 6, 12, 40, 41, 44). Glycoprotein D 49 
(gD) is accepted as the critical and essential receptor-binding protein 50 
of many alpha herpesviruses (reviewed in (8, 48). The main gD 51 
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receptors identified to date include members of the tumor necrosis 52 
factor (TNF) receptor family (HveA) and the poliovirus receptor family 53 
(HveB or nectin 2 and HveC or nectin 1) (28, 42, 51). Furthermore, a 54 
modified form of heparan sulfate, 3-O-sulfated heparan sulfate, can 55 
mediate herpesvirus entry (46). J1.1-2 cells (J cells) represent a 56 
subpopulation of thymidine kinase negative baby hamster kidney 57 
(BHK) cells, selected for their property to be resistant against 58 
infection with herpes simplex virus type 1 (HSV-1), HSV-2 and BoHV-59 
1. Expression of nectin 1 in those cells, rendered them susceptible to 60 
BoHV-1 infection and replication, which suggests that nectin 1 can 61 
serve as a receptor for BoHV-1 gD (gD1) (16, 18, 28). Interestingly, 62 
we observed that BoHV-5 was able to productively replicate in J cells 63 
without the nectin 1 receptor.  64 
According to the published sequence comparison of BoHV-1 and 65 
BoHV-5 (21), the highest divergence between the two viruses map 66 
with the latency-related region and the immediate early proteins (less 67 
than 75% aa identity) BICP0, BICP4, and BICP22. Glycoprotein E 68 
(gE) was also listed in this category, with 74% aa identity between gE 69 
of BoHV-1 (gE1) and gE5. This fact gave also ample reason to try 70 
mapping the neurovirulent phenotype of BoHV-5 to the gE5 molecule 71 
(3, 4, 13). In contrast, the highest sequence similarities between the 72 
two viruses have been described in proteins involved in viral DNA 73 
replication and processing as well as certain virion proteins. Among 74 
others, the predicted aa sequences of gD1 and gD5 were listed as 75 
being identical to 98% (21). However, our own analysis, using the 76 
European Molecular biology Software suite (43), revealed only 79.9% 77 
aa identity. Obviously, the most extensive difference between gD1 78 
 
4/40 
and gD5 maps to a glycine-rich stretch located in the molecule's 79 
ectodomain, between aa 280 and 330 of gD5, in the close vicinity to 80 
the transmembrane region.  81 
Based on these considerations, we hypothesized that BoHV-5 was 82 
able to make use of a cellular receptor that is unavailable to BoHV-1. 83 
To test this hypothesis, the gD genes were removed from bacterial 84 
artificial chromosomes (BACs) harboring the genomes of either 85 
BoHV-5 or BoHV-1 (27). In a second step, gD-exchange viruses were 86 
created by cotransfecting the gD-less BACs with appropriate 87 
plasmids carrying either gD1 or gD5 genes and appropriate flanking 88 
sequences. The newly generated viruses included an intertypic 89 
BoHV-5 mutant carrying gD1 in the place of gD5 and a corresponding 90 
BoHV-1 carrying gD5. These mutants, together with appropriate 91 
revertant mutants, were then used to explore in vitro their ability to 92 
infect J cells and in vivo, in a previously established mouse model, 93 
their ability to cause neurological disease and invade the brain (2). 94 
Our results indicate that gD5 confers an extended host range to 95 
BoHV-1 but is non-essential for invasion of the brain.  96 
Materials and Methods 97 
Viruses and cells.  98 
Madin Darby bovine kidney (MDBK) cells, SV40 transformed African 99 
green monkey kidney (COS-1) cells and J1.1-2 cells (J cells) were 100 
grown at 37oC and 5% CO2 in Dulbecco’s modified Eagle’s medium 101 
(DMEM) supplemented with a mixture of penicillin and streptomycin 102 
and 5% to 10% fetal calf serum (FCS). J cells are derived from 103 
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BHKtk− cells and have been selected for resistance against HSV 104 
infection (16). Vero 2.2 cells were grown in DMEM supplemented with 105 
G418 (500 µg/ml), 10% FCS at 37oC and 5% CO2 (47). Wt BoHV-5 106 
(strain N569), wtBoHV-1 (strain Jura); and recombinant (r) BoHV-5, 107 
rBoHV-5gD1HA, rBoHV-1, rBoHV-1gD5V5, recombinant-revertant (rr) 108 
BoHV-5gD5V5 and rrBoHV-1gD1YFP were propagated in MDBK 109 
cells as described previously (25, 40). 110 
Mice.  111 
All animals were cared for and used in accordance with Swiss laws 112 
for animal experimentation. The mouse strain AR129 used 113 
throughout this study is derived from 129Sv/Ev (H-2b) mice. AR129 114 
mice are with genetically deleted type 1 interferon receptors 115 
combined with RAG-2 knockout (30). 116 
Plasmids. 117 
More details of all constructions are provided in supplementary data. 118 
All primers are listed in Table 1. 119 
p118 contains a gene expression cassette providing kanamycin 120 
resistance flanked by two FRT sites (see also supplementary data). 121 
p302∆gD1HA contains a gene expression cassette providing 122 
kanamycin resistance flanked by two FRT sites, and homology arms 123 
to target the glycoprotein D locus of fBoHV-5 BAC (gD5). The primers 124 
P1, P2, P3, and P4 were used for amplification and cloning of the 125 
homology arms, i.e. 477 bp upstream and 421 bp downstream of 126 
gD5, respectively.  127 
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p302∆kanR contains the same homology arms as p302∆gD1HA. In 128 
this construct, they flank the gD1 ORF, which is fused to an HA- 129 
epitope coding sequence at its 3’ end. Primers P5 and P6 were used 130 
for amplification and cloning of the gD1HA ORF.  131 
p309 contains homology arms to target the gD5 locus, which flank 132 
the gD5 ORF fused to a V5 epitope sequence at its 3’ end. Primers 133 
P7 and P8 were used for amplification and cloning of the gD5V5 134 
ORF.  135 
p307 contains a gD5V5 ORF, flanked with extended homology arms 136 
to target the gD1 locus. The upstream 1134 bp homology arm was 137 
amplified with primers P9 and P10. The downstream 1136 bp 138 
homology arm was amplified with primers P11 and P12.  139 
pCS156 has a total size of 7107 bp and contains a 4182 bp fragment 140 
consisting of gD1 fused to the yellow florescent protein (YFP) coding 141 
sequences, flanked by homology arms to target the gD1 locus. The 142 
upstream homology arm, together with the gD1 coding sequence 143 
without stop codon, was amplified with primers P13 and P14. The 144 
downstream homology arm was amplified with primers P15 and P16. 145 
The YFP sequence was amplified with primers P17 and P18.  146 
Red recombinations for gD deleted BoHV BACs. 147 
fBoHV-5∆gDkanR BAC: The vector p302∆gD1HA was used for 148 
construction of fBoHV-5∆gDkanR BAC by Red recombination (19). 149 
The 2832 bp transfer fragment containing 477 bp upstream of gD5 150 
start codon, kanamycin cassette flanked by FRT sites and 421 bp 151 
downstream of gD5 stop codon was excised with HpaI from 152 
p302∆gD1HA, gel purified and electroporated into arabinose-induced 153 
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E. coli strain DH10B harboring fBoHV5 BAC and pKD46 (19). 154 
Electroporated cells were selected on LB agar plates containing 25 155 
µg/ml kanamycin. The resulting recombinant BoHV-5 BAC was 156 
designated fBoHV-5∆gDkanR. 157 
fBoHV-1∆gDkanR BAC: The 2010 bp DNA transfer fragment was 158 
amplified by PCR using p118 as a template. It contains a kanamycin 159 
cassette for selection in E. coli, flanked by 50 bp homology upstream 160 
of the start codon of gD1 ORF and 50 bp homology downstream of 161 
the stop codon of the gD1 ORF. The P19 and P20 primers used for 162 
amplification are listed in Table 1. The resulting PCR product was 163 
DpnI digested in order to remove residual template DNA. Next, the 164 
transfer fragment was electroporated into arabinose-induced E. coli 165 
strain DH10B harboring fBoHV-1 BAC and pKD46 (19). 166 
Electroporated cells were selected on LB agar plates containing 25 167 
µg/ml kanamycin. The resulting recombinant BoHV1 BAC was 168 
designated fBoHV1∆gDkanR. 169 
DNA preparation from virions.  170 
Herpesviral DNAs were extracted as described previously (23).  171 
Generation of recombinant viruses.  172 
rBoHV-5gD1HA: To generate the gD-exchanged recombinant, 173 
BoHV-5 expressing BoHV-1 gD, p302∆kanR was digested with HpaI, 174 
gel purified and cotransfected with fBoHV-5∆gDkanR BAC DNA into 175 
Vero 2.2 cells by Lipofectamin (Invitrogen) as described before (45). 176 
fBoHV-5∆gDkanR BAC DNA transfected alone did not lead to viral 177 
progeny. However, after cotransfection with the purified fragment 178 
 
8/40 
from p302∆kanR, rBoHV-5gD1HA emerged and was passaged three 179 
times in MDBK cells.  180 
rrBoHV-5gD5V5: To generate the BoHV-5 gD revertant, HpaI 181 
digested and gel purified fragment derived from p309 was 182 
cotransfected with fBoHV-5∆gDkanR BAC DNA into Vero 2.2 cells as 183 
a described before. The resulting recombinant virus progeny-rrBoHV-184 
5gDV5 was passaged three times in MDBK cells. 185 
rBoHV-1gD5V5: To generate the gD-exchanged BoHV-1 186 
recombinant expressing BoHV-5 gD (rBoHV-1gD5V5), a HpaI 187 
digested and gel purified fragment derived from p307 vector and 188 
fBoHV-1∆gDkanR BAC DNA were cotransfected into COS-1 cells as 189 
described before. The resulting recombinant virus progeny, rBoHV-190 
1gD5V5 was passaged three times in MDBK cells. 191 
rrBoHV-1gD1YFP: To generate the BoHV-1 gD revertant mutant, the 192 
vector pCS156 was XbaI/EcoRI digested, gel purified and 193 
cotransfected with fBoHV-1∆gDkanR DNA into MDBK cells as 194 
described before. The resulting recombinant virus progeny-rrBoHV-195 
1gD1YFP was passaged three times in MDBK cells. 196 
Cre mediated excision of F-plasmid in BAC derived BoHV 197 
recombinats. 198 
MBDK cells were cotransfected with DNA of selected viral mutants 199 
and cre expressing vector p116.006 (20). Three days post 200 
transfection five viral plaques were randomly collected and plaque 201 
purified three times. Finally, viral DNA from non-GFP fluorescent 202 
progeny was extracted and characterized by restriction enzyme 203 
analysis in order to verify the deletion of the BAC cassette. 204 
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For the in vitro experiments, the BAC cassette from rrBoHV-205 
1gD1YFP was deleted by cre mediated recombination and selection 206 
of GFP-negative, YFP-positive progeny virus. However, the BAC 207 
cassette in the other recombinant viruses used in this study was 208 
retained in order to have permanent in vitro tracers. For the in vivo 209 
experiments performed in this study the BAC cassette in rBoHV-210 
1gD5V5 and rBoHV-5gD1HA viruses was deleted in order to obtain 211 
virulence close to respective wild type viruses (data not shown). 212 
Indirect Immunofluorescence. 213 
MDBK infected cells or J1.1-2 cells were infected and incubated until 214 
discernible plaques had formed. Then, they were fixed in 3% 215 
paraformaldehyde and permeabilized with 0.2% Triton X-100 (Fluka 216 
Chemie). After blocking with 2% albumin from bovine serum (BSA) 217 
(Sigma-Aldrich), they were incubated with mouse monoclonal IgG2a 218 
(1:500 in PBS) against either the HA-epitope (Santa Cruz 219 
Biotechnology) or the V5-epitope (Invitrogen). For visulization Cy3TM 220 
conjugated AffiniPure goat anti-mouse IgG was used (Jackson 221 
ImmunoResearch Laboratories).  222 
Southern Blot Hybridization.  223 
Digested virus and BAC DNAs were separated on 0.7% agarose gels 224 
for 24 to 48 h at 30 V and then transferred overnight to nylon 225 
membrane (Roche). Transferred DNA was then hybridized with gD5-226 
DIG or gD1-DIG labeled probes overnight at 68°C. For detection by 227 
chemiluminescence, CDP-Star substrate (Roche) was used. The 228 
gD5-DIG and the gD1-DIG labeled probes were amplified by PCR 229 
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(PCR DIG Probe Synthesis Kit, Roche). The primers used for 230 
amplification (gD5upper; gD5lower and gD1upper; gD1lower) are 231 
listed in Table 1.  232 
Virus growth analysis.  233 
MDBK cells were infected with respective viruses either at moi 0.01 234 
or moi 5. After 2 h at 4°C, the temperature was shifted for 1 h to 37°C 235 
to allow virus penetration. The inoculum was removed before the 236 
cells were washed twice with PBS and overlaid with fresh DMEM. At 237 
0, 24, 48, 72, and 96 h (moi = 0.01) and 0, 6, 12, 18, and 24 h (moi = 238 
5) following the temperature shift, the infected cells were scraped into 239 
the culture medium and clarified by centrifugation (311 x g for 10 240 
min). The supernatant was then removed to be analyzed separately. 241 
The cell pellet was resuspended in fresh DMEM. Infectious virus was 242 
harvested following three cycles of freezing/thawing and low speed 243 
centrifugation to remove cell debris. Infectivity in the supernatants 244 
and the pellets was titrated separately in 96 well plates. Each titration 245 
was performed in three independent assays. Viral titers were 246 
determined as TCID50/ml in MDBK cells.  247 
Soluble receptors.  248 
The following soluble receptors carrying either the entire ectodomain 249 
(VCC) or the single N-terminal V domain (V) of human nectins were 250 
used as previously described: human nectin 1 (N1(V)-Fc); human 251 
nectin 2 (N2(V)-Fc); human nectin 3 (N3(VCC)-Fc); human nectin 4 252 
N4(VCC)-Fc (14, 15, 24, 38). Briefly, the PCR amplification products 253 
were cloned in the COS Fc Link vector (SmithKline Beecham) and 254 
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transfected in COS cells with FuGENE6, according to the 255 
manufacturer's instructions. The SARS-S –Fc construct was a gift 256 
from dr. F. Neipel, Erlangen University. The ectodomain of SARS-S 257 
was cloned in pAB61 vector (7) and transfected in HEK 293T cells. 258 
Soluble proteins were affinity purified from cell media on Affigel-259 
protein-A or HiTrap-protein-A, as detailed and referenced elsewhere 260 
(7, 14, 37).  261 
Inhibition of infection.  262 
Soluble receptor proteins were incubated with stocks of infectious 263 
virus in order to test for inhibition of infection. Triplicate aliquots of 264 
rBoHV-5 and rBoHV-1gD5V5, corresponding to a concentration of 265 
moi 5 for 20.000 MDBK cells, were preincubated individually with 266 
each of the soluble receptors at a 200 nanomolar (nM) concentration. 267 
200 nM SARS-S spike glycoprotein, 200 nM BSA or D’MEM without 268 
added proteins were used as controls. After 1 hour incubation at 269 
37°C, the aliquots were transferred to J-cell monolayers in 96 well 270 
plates. After 2 hours, these inocula were removed and the cells were 271 
supplemented with 100 µl fresh medium before incubating at 37°C for 272 
48 hours. Emergence of plaques was recorded and GFP-positive 273 
cells were counted under the fluorescence microscope.  274 
Design of the animal experiments.  275 
43 AR129 mice (8 weeks of age, all female) were divided into groups 276 
of 7 to 10 and used for intraperitoneal (i.p.) inoculation with 107 50% 277 
tissue culture infective doses (TCID50) of the viruses specified in 278 
 
12/40 
Table 2. Four siblings of the same mice were used as mock-infected 279 
controls.  280 
Individual mice were euthanized as soon as they developed severe 281 
disease symptoms. Exceptions are listed in Table 2. At necropsy the 282 
brain, kidney, liver, spleen, intestine and lung were collected. Each 283 
organ was divided into two parts. One part was fixed with formalin 284 
solution in order to be used for hematoxylin and eosin (HE) staining 285 
or immunohistochemistry (IHC). The remaining part was shock-frozen 286 
in liquid nitrogen and conserved at -80°C for further analysis by real 287 
time PCR. 288 
DNA detection and quantification.  289 
Primers and probes for quantitative real-time PCR (TaqMan) used to 290 
amplify sequences within the open reading frames of the glycoprotein 291 
B of BoHV-1 and BoHV-5, PCR conditions, and usage of plasmid 292 
positive controls were performed as previously described (2). For the 293 
internal control, the previously developed TaqMan assay reagent for 294 
the 18S rRNA kit was used (AB), according to the manufacturer. The 295 
data were analyzed on a 7900 HT Fast Real Time System detector 296 
(AB). The absolute quantitation of virus copies per cell was done 297 
according to AB User Bulletin 2 as previously described (2). 298 
Extraction of viral DNA from mouse brains.  299 
The tissue from one half-brain, sagitally divided was homogenised by 300 
TissueRuptor (QIAGEN) and DNA from 50 mg of brain was extracted 301 
by using the QIAamp DNA Mini kit (QIAGEN). 302 
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Immunohistology and antigen detection.  303 
Immunohistology was performed with paraffin-embedded brain, 304 
kidney, liver, spleen, intestine and lung tissue sections fixed in 305 
formalin solution (4%). 3 to 4 micrometer thick organ sections were 306 
mounted on positively charged slides and then deparaffinized in 307 
xylene and rehydrated by being dipped in a graded ethanol series 308 
(100, 96, and 70%). After a counterstaining in hemalaun for 4 min 309 
and washing in water at ambient temperature, the sections were 310 
digested with a Proteinase K solution (DAKO REALTM Proteinase K 311 
diluent, S2032 and 40x concentrate, S2019) for 10 min at room 312 
temperature (RT). Afterwards endogenous peroxidase activity was 313 
blocked by incubation in 3% H2O2 for 15 min and nonspecific binding 314 
of antibodies was eliminated by treatment with blocking solution 315 
(protein block serum-free, DAKOCytomation, X0909) for 10 min at 316 
RT. The sections were then incubated over night with the monoclonal 317 
antibody 141 (specific for gC of both BoHV-1 and BoHV-5 (35) at a 318 
1:20 dilution in phosphate buffered saline (PBS) (pH 8) and for 30 319 
min with a anti-mouse secondary antibody conjugate containing a 320 
dextran polymer labeled with horseradish peroxidase (Dako, EnVision 321 
K4001). Incubations were done at room temperature. Between every 322 
step slides were rinsed with PBS (Phosphate Buffer Saline, pH 8). 323 
The development of the color reaction by the aminoethyl carbazole 324 
substrate (AEC (Red) substrate kit, Invitrogen 00-2007), added after 325 
washings, was under the microscope and stopped by rinsing with 326 




Generation and genotypic characterization recombinant BoHV-5 329 
and BoHV-1- with intertypic gD.  330 
A two-step strategy was used to exchange the gD encoding 331 
sequences between BoHV-5 and BoHV-1. In a first step, previously 332 
described BACs (27), harboring the genomes of either BoHV-1 333 
(fBoHV-1) or BoHV-5 (fBoHV-5), were used to replace the gD-coding 334 
sequences by a kanamycin resistance cassette (see supplementary 335 
information S1). 336 
In a second series of experiments, infectious viruses were rescued by 337 
homologous recombination. Notably, gD-less BACs did not provide 338 
infectious progeny upon transfection. Therefore, gD-less BAC DNAs 339 
were cotransfected with plasmids containing gD sequences 340 
supplemented with marker tags and appropriate flanking sequences. 341 
As a result, the following four new viruses were generated and 342 
characterized by restriction enzyme analysis and Southern blot as 343 
well as by identification of their markers (see supplementary 344 
information S1). (1) rBoHV-1gD5V5, a BoHV-1, which encoded gD5 345 
with a V5 tag at its C-terminus; (2) rrBoHV-1gD1YFP, a rescue virus, 346 
which encoded gD1 with a yellow fluorescent protein fused to its C-347 
terminus; (3) rBoHV-5gD1HA, a BoHV-5 mutant expressing gD1 with 348 
an HA-tag fused to its C-terminus; (4) rrBoHV-5gD5V5, a rescue 349 
mutant differing from its ancestor for a gD5 fused to a C-terminal V5-350 
tag.  351 
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Marker-tag analysis of the newly generated viruses. 352 
Three of the new viruses carried a gD fused to a C-terminal epitope, 353 
which was expected to be recognized by appropriate monoclonal 354 
antibodies. The fourth virus carried a yellow fluorescent protein 355 
marker. To test for the presence and functionality of those markers, 356 
MDBK cells were infected with parent, mutant, and rescue viruses 357 
and analyzed for plaque development by fluorescent microscopy (Fig. 358 
1, panels A through F). Emerging green fluorescence was due to 359 
replication of the viruses and based on the expression of a GFP 360 
cassette embedded in the BAC sequences. Replication and plaque 361 
formation of those viruses provided evidence that they all contained a 362 
functional gD. To avoid interference between yellow and green 363 
fluorescence in rrBoHV-1gD1YFP, the GFP cassette was removed 364 
from this virus by Cre recombination and this rescue virus was shown 365 
to provide yellow fluorescence in the absence of green fluorescence 366 
(panel F). After successful plaque development, the monolayers were 367 
fixed for immunolabeling with appropriate monoclonal antibodies. As 368 
shown in panels A’ through E’, each virus with a predicted tag did 369 
react properly in this assay. Thus, each of the new viruses could be 370 
addressed by fluorescence and/or immunohistology. (See also 371 
supplementary information Fig. S2 and S3) 372 
Viral growth analysis. 373 
Both cell-free and cell-associated virus production was determined by 374 
growth curve experiments. Each analysis was done in triplicate. The 375 
results, shown in Fig. 2, indicated that all mutant and revertant 376 
viruses grew with similar kinetics and to similar titers as their wild type 377 
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ancestors. Thus, the growth in MDBK cells of the different viruses 378 
was not significantly affected, neither by the exchange of gD nor from 379 
retaining the BAC cassettes within the viral genome. (See also 380 
supplementary information Fig. S4) 381 
Type-specific gD determines the host range of BoHV-1 and -5 in 382 
vitro. 383 
J1.1-2 cells (J cells) are known to be resistant against infection with 384 
HSV-1, HSV-2 and BoHV-1 (16). However, we had previously 385 
observed that they were susceptible to BoHV-5. To test, whether this 386 
property could be mapped to gD5, we produced viral stocks in MDBK 387 
cells and inoculated J cells with the different viruses, using equal 388 
infectious doses (moi 5) as determined by titration in MDBK cells. The 389 
results at 72 hpi are shown in Fig. 3. Mock infection or infection with 390 
BoHV-1 did not lead at all to plaque formation (panels A, B, C). In 391 
contrast, fluorescent plaques developed continuously over time upon 392 
inoculation of J cells with either BoHV-5 or BoHV-1gD5 (panels E, G). 393 
Plaques due to infection with the latter virus could also be stained 394 
immunologically by using a monoclonal antibody against the V5-tag 395 
(panel H). Wild type gD5 (panel F) did not react with monoclonal 396 
antibodies against the HA-tag. However, inoculation with BoHV-5gD1 397 
did occasionally lead to the detection of single green fluorescent J 398 
cells (panel I). As expected, such cells could also be stained with a 399 
monoclonal antibody against the HA-tag (panel J). However, neither 400 
spread of the virus infection to neighboring cells nor plaque formation 401 
was observed.  402 
 
17/40 
In summary, these data strongly indicate that BoHV-5 can use host 403 
entry receptors, which are generally not accessible for BoHV-1 and 404 
that gD5 contributes a major part to the apparent host-range 405 
divergence of the two viruses in vitro. 406 
Inhibition of infection by pre-incubation with soluble nectins.  407 
J cells lack nectin 1, nectin 2, and HevA but express the nectin 3 408 
ortholog of human nectin 3 (15, 16). Since gD5 was able to mediate 409 
infection of J cells with BoHV-5 and rBoHV-1gD5, the question arose, 410 
whether or not saturating gD5 with the ectodomain of human nectin 3 411 
could block infectivity. Therefore, replicate aliquots of infectious virus 412 
stocks were preincubated before inoculation of J cells with each one 413 
of the following soluble receptors: human nectin 1, human nectin 2, 414 
human nectin 3, and human nectin 4, respectively (for details see 415 
materials and methods) (14, 15, 24, 38). Preincubations with equal 416 
concentrations of BSA or SARS-S glycoprotein or DMEM without 417 
added protein were used as controls. 48 hrs after inoculation, 418 
emergence of plaques was recorded and GFP-positive cells were 419 
counted under the fluorescence microscope. The results are 420 
summarized in Figure 4 (see also Figures S5-S7). Human nectin 3 421 
reduced the number of infectious events with rBoHV-5 and rBoHV-422 
1gD5V5 in J cells almost completely. When compared to human 423 
nectin 3, human nectin 1 exerted a somewhat lower effect, whereas 424 
human nectins 2 and 4 provided an intermediate effect (80 to 90% 425 
reduction). As expected, BSA (in comparison to incubation without 426 
protein) affected infectivity only marginally. As a further negative 427 
control, we used a totally unrelated protein, the surface protein S of 428 
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Severe Acute Respiratory Syndrome Coronavirus (SARS-S). 429 
According to our experience, addition of such negative controls may 430 
inhibit virus infection by about 25% (14). Addition of SARS-S-Fc 431 
reduced virus infectivity between 25% and 40% as compared to BSA.  432 
Using the one-way analysis of variance and either Dunnet’s or also 433 
Newman-Keuls multiple comparison test, we found that the difference 434 
between BSA and SARS-S was not statistically significant. Inhibition 435 
of BoHV-5gD with nectin 1 was significant against BSA (p<0.05) but 436 
not against SARS-S. All other competitors provided significant 437 
inhibition compared to either BSA or SARS-S. There was no 438 
significant difference in between of the effects of various nectins. The 439 
results indicate that gD5 was able to interact with a variety of soluble 440 
human nectins, even though their native counterparts were not 441 
expressed in J cells. The differences between nectin 3 on one side 442 
and nectin 1, 2, 4 on the other side may reflect different affinity of gD5 443 
to the various nectins. Altogether, these experiments suggested that 444 
gD5 carries binding sites for a number of receptors and their human 445 
orthologs. Thus, the gD5 receptor-binding domain(s) seem to act in a 446 
rather promiscuous manner, which is surprising when compared to wt 447 
HSV-1 and unrestricted HSV-1 mutants (15).  448 
Infection of AR129 mice 449 
Having established that rBoHV-1gD5 had an extended host range in 450 
vitro, it was of interest to know its properties in vivo. For this purpose, 451 
groups of 7 to 10 AR129 mice were inoculated intraperitoneally with 452 
107 TCID50 of either BoHV-5, BoHV-1, rBoHV-1gD5, rBoHV-5gD1, or 453 
rrBoHV-1. For animal welfare reasons, all animals were checked 454 
twice daily for clinical symptoms and were euthanized upon 455 
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development of severe disease. The healthy animals at a given time 456 
point post inoculation were considered “survivors”. A chart showing 457 
the survival times of the animals in each group is presented in Fig. 5. 458 
Both clinically and in terms of survival, the mice could be divided into 459 
two statistically significant different groups. Mice inoculated with 460 
wtBoHV-5, BoHV-5gD1, and BoHV-1gD5 experienced an early onset 461 
of disease and had to be euthanized significantly earlier (mean 12 to 462 
15 dpi) than the mice inoculated with either wtBoHV-1 or rrBoHV-1 463 
(mean 22 to 25 dpi). The calculated p-values for significant 464 
differences varied between 0.001 and 0.005 (Gehan-Breslow-465 
Wilcoxon Test).  466 
Erected fur was the single clinical symptom that was observed in all 467 
mice that succumbed to disease. Surprisingly, all diseased mice 468 
showed central nervous symptoms, although two different types could 469 
be distinguished and grouped with the virus used for inoculation. 470 
Diseased mice of three groups (BoHV-1, rrBoHV-1, and rBoHV-471 
1gD5) showed ataxia, weakness in the rear limbs, and hunched back. 472 
The mice inoculated with either BoHV-5 or rBoHV-5gD1 showed even 473 
more severe neurological symptoms, i.e. stumbling, body tremor, 474 
ptosis, distorted body shape. Only mice inoculated with BoHV-5 475 
showed also body-turn-over and apparent pain during walking.  476 
Taken together, two surprises came with these experiments. First, the 477 
fact that BoHV-1-infected mice developed a disease with neurological 478 
symptoms, although with a significant delay. Second, the mice 479 
inoculated with BoHV-1gD5 grouped with BoHV-5 in terms of survival 480 
time and with BoHV-1 in terms of clinical disease signs.  481 
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We conclude from this experiment that BoHV-1gD5 was significantly 482 
more virulent in AR129 mice than either its parent BoHV-1 or its 483 
rescue mutant rrBoHV-1gD1. Indeed, it seemed that the BoHV-1 484 
mutant carrying gD5 was almost equally virulent as the neurotropic 485 
virus BoHV-5. However, BoHV-5gD1 was indistinguishable from 486 
BoHV-5 both in terms of survival time and type of clinical disease.  487 
Invasion of the brain.  488 
To initially test whether or not the disease signs in the mice could be 489 
associated to the ability of the respective viruses to invade the brain, 490 
DNA was extracted from brain samples and subjected to real-time 491 
PCR analysis. Based on the results (Fig. 6), it was possible to divide 492 
the mice into two significantly different groups (unpaired t test; 493 
p<0.01), those with high yields of viral DNA in the brain (BoHV-5 and 494 
rBoHV-5gD1) and those with low or no yields of viral DNA in the brain 495 
(BoHV-1, rBoHV-1gD5, and rrBoHV-1gD1). As expected for this type 496 
of mice, no histological signs of encephalitis could be detected in any 497 
of the brain samples upon HE staining (Fig. 7).  498 
However, upon immunohistological staining, using a monoclonal 499 
antibody recognizing gC of both BoHV-1 and BoHV-5, viral antigen 500 
could be detected in neurons in 7 out of 10 brain stems of mice 501 
inoculated with BoHV-5 and all seven brains of mice inoculated with 502 
BoHV-5gD1 (Fig. 7). In contrast, we did not detect any viral antigen in 503 
the brain sections from all the other mice.  504 
We conclude from these experiments that invasion of the brain is a 505 
property of BoHV-5 but does not reside within gD5. Indeed, gD5 is 506 




The present study focused on the contributions of the type-specific 509 
entry-mediator-binding glycoproteins gD, specified by either BoHV-1 510 
or BoHV-5, to infectivity of cell cultures and virulence in vivo, which 511 
led to the following new insights: 512 
(1) gD was interchangeable between BoHV-1 and BoHV-5 without 513 
significantly affecting the replication properties of the respective 514 
viruses in conventional cell cultures. 515 
(2) However, type-specific gD was able to determine the host range 516 
of both BoHV-1 and -5. Interestingly, gD1 was associated with a 517 
narrow host range, whereas gD5 provided the ability to infect cells 518 
that were not accessible through gD1.  519 
(3) To explore this further, viruses carrying gD5 were tested for their 520 
ability to be blocked by a range of soluble receptor molecules, i.e. 521 
nectins 1, 2, 3, 4 or control proteins, such as SARS glycoprotein S or 522 
BSA. Surprisingly, all four nectins were able to abolish the infectivity 523 
of viruses carrying gD5. In contrast, the control protein BSA had 524 
almost no effect. Interestingly, the SARS-S glycoprotein was able to 525 
interfere with infectivity, at least to a limited extent. Since SARS-S 526 
glycoprotein targets the angiotensin-converting enzyme 2 (ACE-2), 527 
which is expressed on the surface of kidney cells, we suggest that 528 
this interference may be attributed to steric hindrance (34). Thus, gD5 529 
was blockable by an extraordinary broad range of nectins.  530 
(4) In vivo, we found that a BoHV-1 mutant carrying gD5 was almost 531 
equally virulent as the neurotropic BoHV-5. However, replacement of 532 
gD5 by gD1 in BoHV-5 did not reduce the ability of this virus to 533 
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invade the brain, while substitution of gD1 with gD5 in BoHV-1 did not 534 
enhance the ability to infect secondary neurons.  535 
Among all of the different herpesvirus entry mediators known to date, 536 
nectin 1 has been shown to serve as a receptor for BoHV-1 (9, 10, 537 
16-18, 26, 28, 49). In contrast, the potential receptors for BoHV-5 538 
have not yet been determined. This study can only partially help to 539 
shed light on this issue. However, the successful inhibition of 540 
infectivity with soluble nectins together with our host-range studies in 541 
vitro, suggests that gD5 may bind to and make use of an extremely 542 
broad range of receptors when compared to its counterparts in other 543 
alpha herpesviruses, such as wild type HSV-1 and unrestricted HSV-544 
1 mutants (15).  545 
The crystal structures of BoHV gDs have not been determined. 546 
However, on the basis of overall similarity and conservation of 547 
cysteine residues throughout the molecules, which greatly determine 548 
the three dimensional structure through disulfide bonds, one may 549 
assume that the general formation of the BoHV gDs should be similar 550 
to HSV gDs (10). Binding of HSV gDs to their entry mediators has 551 
been mapped predominantly to the N-terminal portion of the 552 
molecule, although more C-terminally located fragments also 553 
contribute to entry functions (10, 17, 26, 49). Therefore, it is 554 
interesting to note that only few differences between gD1 and gD5, 555 
i.e. 6 aa substitutions, map within the first 100 aa from the N-terminus 556 
of the mature BoHV gD molecules (1 and our data). However, gD5 557 
differs from gD1 in an N-linked glycosylation site (aa 23 to 25, NYT). 558 
Threonine at position 25 in gD1 is replaced by isoleucine in gD5, 559 
which abrogates the glycosylation site (1, 50). We suggest that, due 560 
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to lesser glycosylation, gD5 might have a more flexible three-561 
dimensional structure, which may facilitate binding to a broader range 562 
of entry mediators. However, glycosylation may not be the one and 563 
single determinant of the broader host-range attributed to gD5. The 564 
highest divergence between gD1 and gD5 maps to a fragment 565 
between aa 280 and 330 of the molecules, which still belongs to the 566 
ectodomain but is located close to the transmembrane region (1). In 567 
HSV gD, this fragment (aa 260 to 310) has been referred to as the 568 
profusion domain (PFD), which is required for interaction with other 569 
viral glycoproteins, i.e. gB, gH, gL, to proceed with the entry process 570 
(26, 29). Interestingly, aa 60 to 210 of HSV gD can be replaced, while 571 
the 210 to 310 segment is essential (39). Having this in mind, it is 572 
interesting to note that, despite of the differences in their PFDs, gD1 573 
and gD5 apparently interacted successfully with their heterologous 574 
interaction partners. However, the details of one gD type interacting 575 
with the other partners of the entry complex may influence the entry 576 
pathway as well as the entire dynamics of viral replication.  577 
The in vivo studies revealed a number of interesting new findings. 578 
Based on our previously established model, we inoculated AR129 579 
mice with our new viruses (2). Unexpectedly, almost all of them 580 
developed neurological symptoms and had to be euthanized before 581 
the planned end of our study. Thus, all of our BAC-derived viruses 582 
had retained a significant degree of neurovirulence. However, 583 
disease developed early or late, depending on the virus type used for 584 
inoculation. Wild type BoHV-1 and the corresponding rescue mutant 585 
showed a delayed onset of disease, whereas wild type BoHV-5 and 586 
BoHV-5gD1 as well as BoHV-1gD5 showed an early onset. Thus, 587 
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gD5 appeared to increase the virulence of BoHV-1, whereas gD1 did 588 
not abrogate the virulence of BoHV-5. Clinically and virologically 589 
(PCR and immunohistology), the mice could also be separated into 590 
two groups. However, in this case BoHV-1gD5 did not group with 591 
BoHV-5 and BoHV-5gD1 but rather with the viruses having BoHV-1 592 
backbones. Only BoHV-5 viruses, regardless of their gD types, were 593 
able to invade and replicate in the brain. This observation is in 594 
agreement with previous reports, which attributed the phenotype of 595 
neuroinvasion to gE, rather than gD (3, 4, 11-13, 36). However, in the 596 
case of BoHVs, the contribution of gD to neuroinvasiveness had not 597 
been addressed previously and it was, therefore, important to look at 598 
it. Nevertheless, these results and considerations cannot explain the 599 
occurrence of neurological disease symptoms in the mice inoculated 600 
with BoHV-1-backbone. In this context, we accidentally observed that 601 
both BoHV-1- and BoHV-5-derived viruses were able to target the 602 
adrenal gland of the mice, causing severe necrosis (data not shown). 603 
The adrenal medulla consists of differentiated post-ganglionic cells, 604 
which may provide direct access to the CNS (33). Indeed, 605 
intraperitoneal inoculation of C3H/HeN mice with HSV-1 leads to 606 
severe adrenal necrosis due to viral replication (31, 32). The same 607 
authors reported that HSV-1 was able to advance from the medullar 608 
gland to the spinal cord and brain stem, thus, causing neurological 609 
symptoms. Presently, we can only speculate that this pathway may 610 
also be open to BoHV-1 and BoHV-5 but this issue presents an 611 
interesting topic for further research. Future work may also focus on 612 
the fine mapping of the receptor-binding fragment of either gD type 613 
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and on the identification of the receptor used by gD5, for example a 614 
bovine ortholog to human nectin 3.  615 
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Table 1. Synthetic oligonucleotides used in this study.  622 
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Table 2. Infection, incubation times, status at necropsy. 629 
Infection Groupa Diseasedb (dpi)c,d Healthye (dpi)c 
BoHV-1 8 5 (18, 20, 23)e 3 (29) 
rrBoHV-1 9 3 (21, 25, 29) 6 (15, 18) 
rBoHV-1gD5 9 8 (14, 15, 18, 19, 23) 1 (26) 
BoHV-5 10 10 (11, 12, 13, 14, 
16, 19, 21, 28) 
0 
rBoHV-5gD1 7 7 (12, 17) 0 
Mock 4 0 4 (17, 29) 
a
= number of animals per group; b=number of animals with disease 630 
signs at the time of necropsy; c= Day of necropsy in parentheses; d= 631 
in this column, dpi equals incubation time; e=number of animals 632 




Figure captions 635 
Fig. 1. Phenotyping of parent, mutant, and rescue viruses by 636 
fluorescence microscopy. MDBK cells were infected with various 637 
viruses to be analyzed at 72 hpi. The top two rows show plaques of 638 
BAC-derived rBoHV-5 and its mutants, whereas the bottom two rows 639 
show BAC-derived rBoHV-1 and its mutants. The top row shows 640 
green fluorescent plaques of A: rBoHV-5; B: rBoHV-5gD1HA; C: 641 
rrBoHV-5gD5V5. For the second row, the same dishes were stained 642 
with mcAbs and a red fluorescent Cy3 conjugate (A' and B': mcAb 643 
against HA-tag; C' mcAb against V5-tag). In the third row, the 644 
following fluorescent plaques are shown: D: green fluorescent rBoHV-645 
1 and E: rBoHV-1gD5V5; F: yellow fluorescent rrBoHV-1gD1EYFP. 646 
For the fourth row (D', E'), the same viruses as in the third row were 647 
stained with mcAb against V5 and a red fluorescent Cy3 conjugate. 648 
Fig. 2. Growth kinetics of recombinant BoHV-5 mutants and 649 
recombinant BoHV-1 mutants versus wt BoHV-5 and wt BoHV-1. 650 
MDBK cells were infected at moi of 0.01 with different viruses and 651 
harvested at various times post inoculation. The virus yields at each 652 
time point were determined by titration. Panels A and B: rBoHV-5 (full 653 
squares); rBoHV-5gD1 (open squares); rBoHV-1 (full circles); rBoHV-654 
1gD5 (open circles). Panels C and D: wt BoHV-5 (full squares); 655 
rrBoHV-5gD5 (open squares); wt BoHV-1 (full circles); rrBoHV-1gD1 656 
(open circles). Cell-free (supernatant, panels A and C) and cell-657 
associated virus (pellets, panels B and D) were titrated separately. 658 
The x-axis represents the time scale post infection. Virus titers (659 
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axis) are expressed as TCID50/ml. Mean values with standard 660 
deviation (error bars) are shown. 661 
Fig. 3. Type-specific gD determines the host range of BoHV-1 662 
and BoHV-5. J cells were mock-infected (top row) or infected at moi 663 
5 with BoHV recombinants, all of which express the green fluorescent 664 
marker upon successful infection and replication. At 72 hpi, cells were 665 
fixed and stained with monoclonal antibodies and a secondary 666 
antibody carrying Cy3. Mock infected cells did neither develop 667 
plaques (A) nor provide any green or red fluorescence (B). rBoHV-1 668 
did neither give rise to green fluorescence (C) nor provide red 669 
fluorescence due to Cy3 conjugate binding to mcAb against V5 (D). 670 
rBoHV-5 caused development of green fluorescent plaques (E) but 671 
did not bind mcAb against HA (F). rBoHV-1gD5V5 caused green 672 
fluorescent plaque formation (G) and binding of mcAb against V5 (H). 673 
rBoHV-5gD1HA provided single green fluorescent cells (I), which also 674 
stained positive with mcAb against the HA-tag (J). 675 
Fig. 4. Inhibition of infection by pre-incubation with soluble 676 
nectins. Relative infectivity rates are shown. Viruses were incubated 677 
with soluble proteins as described in materials and methods before 678 
being inoculated onto monolayers of J cells. Fluorescent cells were 679 
counted at 48 hpi. Fluorescent cell numbers emerging from virus 680 
incubated with 200 nM BSA were set as 100% (bars measured on y-681 
axis). The identities of the proteins used for co-incubation with virus 682 
stocks are indicated beneath each pair of bars. Grey bars represent 683 
infection with rBoHV-5, black bars confer to rBoHV-1gD5V5. Each 684 
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experiment was done at least in triplicate (mean values are shown 685 
and the error bars represent the standard error of the mean). 686 
Fig. 5. Survival times of AR129 mice upon infection with different 687 
BoHVs. Groups of 7 to 10 mice were inoculated intraperitoneally 107 688 
TCID50 of virus and checked daily twice for their health status. They 689 
were euthanized upon development of severe disease symptoms. 690 
The x-axis gives the survival times post inoculation. The y-axis gives 691 
the percentage of mice in each group at any given time point. The 692 
symbols used for each virus are given on the right of the figure.  693 
Fig. 6. DNA of BoHV-5 and BoHV-5gD1 in brain tissue. DNA was 694 
extracted from the brains of each animal and subjected for real time 695 
PCR and quantification of the viral DNA load per cell as described in 696 
Materials and Methods. The viruses used for inoculation are listed on 697 
the x-axis. Box plots refer to the y-axis and show mean values, the 698 
75th percentile (box) as well as maximal and minimal values 699 
(whiskers).  700 
Fig. 7. Histology (HE) and immunohistology of brain sections. A) 701 
HE staining of a section of mouse brain from an animal inoculated 702 
with BoHV-1. This picture is representative for all sections analyzed, 703 
independent of the inoculated virus. B,C,D) Immunohistology using a 704 
monoclonal antibody, recognizing gC of both viruses BoHV-1 and 705 
BoHV-5. B) Negative brain section of a mouse inoculated with BoHV-706 
1. This picture is representative for all brain sections from mice 707 
inoculated with either BoHV-1, BoHV-1gD5, and rrBoHV-1. C) 708 
Representative picture of a brain section from a mouse inoculated 709 
with rBoHV-5gD1. This picture is also representative for animals 710 
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inoculated with BoHV-5. Neurons in the brain stem area show a 711 
positive intracytoplasmic staining (red cytoplasmic staining). D) 712 
Cutout of the section outlined in C. Bar: 100 µm. 713 
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